Shifting patterns in the interpretation of phase iii clinical trial outcomes in advanced non-small-cell lung cancer: The bar is dropping

Journal of Clinical Oncology

Volumn 32, Issue 14, 2014, Pages 1407-1411

  Sacher, Adrian G ^a   Le, Lisa W ^a   Leighl, Natasha B ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; SYSTEMIC THERAPY; LUNG TUMOR; METHODOLOGY; MORTALITY; PHASE 3 CLINICAL TRIAL (TOPIC); STANDARD; TREATMENT OUTCOME;

CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; LUNG NEOPLASMS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 84902829674     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.52.7804     Document Type: Article

References (27)

1. Howlader N, Noone AM, Krapcho M, et al (eds): SEER Cancer Statistics Review, 1975-2009. Bethesda, MD, National Cancer Institute, 2012
2. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62:10-29, 2012
3. Le Chevalier T, Brisgand D, Douillard JY, et al: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients. J Clin Oncol 12:360-367, 1994
4. Shepherd FA, Dancey J, Ramlau R, et al: Prospective randomized trial of docetaxel versus best supportive care in patients with non-smallcell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095-2103, 2000 (Pubitemid 30324363)
5. Belani CP, Pereira JR, von Pawel J, et al: Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life: A randomized controlled trial. Lung Cancer 53:231-239, 2006 (Pubitemid 44043122)
6. Hanna N, Shepherd FA, Fossella FV, et al: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-1597, 2004 (Pubitemid 41079796)
7. Scagliotti GV, Parikh P, von Pawel J, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapynaive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543-3551, 2008
8. Rosell R, Gatzemeier U, Betticher DC, et al: Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: A cooperative multinational trial. Ann Oncol 13:1539-1549, 2002 (Pubitemid 35331451)
9. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98, 2002 (Pubitemid 34438899)
10. Ardizzoni A, Boni L, Tiseo M, et al: Cisplatinversus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: An individual patient data meta-analysis. J Natl Cancer Inst 99:847-857, 2007
11. Le Chevalier T, Scagliotti G, Natale R, et al: Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: A meta-analysis of survival outcomes. Lung Cancer 47:69-80, 2005 (Pubitemid 39643243)
12. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2009
13. Kwak EL, Bang YJ, Camidge DR, et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693-1703, 2010
14. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005 (Pubitemid 41058344)
15. Garon EB: Issues surrounding clinical trial endpoints in solid malignancies with a focus on metastatic non-small cell lung cancer. Lung Cancer 77:475-481, 2012
16. Burzykowski T, Buyse M, Piccart-Gebhart MJ, et al: Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol 26:1987-1992, 2008
17. Soria JC, Massard C, Le Chevalier T, et al: Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy? Ann Oncol 21:2324-2332, 2010
18. Sargent DJ, Hayes DF: Assessing the measure of a new drug: Is survival the only thing that matters? J Clin Oncol 26:1922-1923, 2008
19. U.S. Department of Health and Human Services, Food and Drug Administration: Guidance for Industry Clinical Trial Endpoints for the Approval of Non-Small Cell Lung Cancer Drugs and Biologics. Rockville, MD, 2011
20. Carney DN: Lung cancer: Time to move on from chemotherapy. N Engl J Med 346:126-128, 2002
21. Ocana A, Tannock IF: When are "positive" clinical trials in oncology truly positive? J Natl Cancer Inst 103:16-20, 2011
22. Rothenberg ML, Carbone DP, Johnson DH: Improving the evaluation of new cancer treatments: Challenges and opportunities. Nat Rev Cancer 3:303-309, 2003 (Pubitemid 37328866)
23. Roberts TG Jr, Lynch TJ Jr, Chabner BA: The phase III trial in the era of targeted therapy: Unraveling the "go or no go" decision. J Clin Oncol 21:3683-3695, 2003
24. Sobrero A, Bruzzi P: Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval. J Clin Oncol 27:5868-5873, 2009
25. Bariani GM, de Celis Ferrari AC, Hoff PM, et al: Self-reported conflicts of interest of authors, trial sponsorship, and the interpretation of editorials and related phase III trials in oncology. J Clin Oncol 31:2289-2295, 2013
26. Turner EH, Matthews AM, Linardatos E, et al: Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 358: 252-260, 2008
27. Breathnach OS, Freidlin B, Conley B, et al: Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: Sobering results. J Clin Oncol 19:1734-1742, 2001 (Pubitemid 32230875)